Earlier this year, the FDA Oncologic Drugs Advisory Committee (ODAC) voted in support of further clinical evaluation of dostarlimab, a novel anti-PD-1 monoclonal antibody, in patients with dMMR/MSI-H locally advanced rectal cancer.